Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

BIERMER

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Antiviral Therapy|June 13, 2022
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis BEd Gane, Man-Fung Yuen, Thomas N Kakuda, et al.
Journal of Hepatology|April 7, 2024
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2Kosh Agarwal, Maria Buti, Florian van Bömmel, et al.
NPJ Vaccines|February 5, 2026
Safety, immunogenicity, and baseline immune correlates of vaccine JNJ-0535 in participants with or without CHBSimon Verheijden, Nádia Conceição-Neto, Stefan Bourgeois, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Gut|January 25, 2023
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infectionHarry L A Janssen, Jinlin Hou, Tarik Asselah, et al.
JHEP Reports : Innovation in Hepatology|December 30, 2025
Corrigendum to "Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study" [JHEP Reports 2025 7(10) 101516]Edward Gane, Ewa Janczewska, Tetsuo Takehara, et al.
JHEP Reports : Innovation in Hepatology|September 8, 2025
Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN studyEdward Gane, Ewa Janczewska, Tetsuo Takehara, et al.
The Lancet. Gastroenterology & Hepatology|July 13, 2023
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trialMan-Fung Yuen, Tarik Asselah, Ira M Jacobson, et al.
Journal of Hepatology|July 23, 2022
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHBMan-Fung Yuen, Stephen Locarnini, Tien Huey Lim, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Antiviral Therapy|June 13, 2022
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis BEd Gane, Man-Fung Yuen, Thomas N Kakuda, et al.
Journal of Hepatology|April 7, 2024
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2Kosh Agarwal, Maria Buti, Florian van Bömmel, et al.
NPJ Vaccines|February 5, 2026
Safety, immunogenicity, and baseline immune correlates of vaccine JNJ-0535 in participants with or without CHBSimon Verheijden, Nádia Conceição-Neto, Stefan Bourgeois, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Gut|January 25, 2023
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infectionHarry L A Janssen, Jinlin Hou, Tarik Asselah, et al.
JHEP Reports : Innovation in Hepatology|December 30, 2025
Corrigendum to "Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study" [JHEP Reports 2025 7(10) 101516]Edward Gane, Ewa Janczewska, Tetsuo Takehara, et al.
JHEP Reports : Innovation in Hepatology|September 8, 2025
Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN studyEdward Gane, Ewa Janczewska, Tetsuo Takehara, et al.
The Lancet. Gastroenterology & Hepatology|July 13, 2023
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trialMan-Fung Yuen, Tarik Asselah, Ira M Jacobson, et al.
Journal of Hepatology|July 23, 2022
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHBMan-Fung Yuen, Stephen Locarnini, Tien Huey Lim, et al.
Pageof 5